Int J Biol Sci 2022; 18(11):4560-4577. doi:10.7150/ijbs.69933 This issue Cite

Research Paper

TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR

Tao Zhang1,2,3*, Bofang Wang2,3*, Fei Su1*, Baohong Gu2,3*, Lin Xiang2,3, Lei Gao2,3, Peng Zheng2,3, Xue-mei Li2,3, Hao Chen2,3,4✉

1. Department of oncology, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
2. The second clinical medical college of Lanzhou university, Lanzhou , Gansu, China.
3. Key laboratory of digestive system tumors, Lanzhou University Second Hospital, Lanzhou, Gansu, China.
4. Cancer center, Lanzhou University Second Hospital, Lanzhou, Gansu, China.
*These authors contributed equally to this work.

Citation:
Zhang T, Wang B, Su F, Gu B, Xiang L, Gao L, Zheng P, Li Xm, Chen H. TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR. Int J Biol Sci 2022; 18(11):4560-4577. doi:10.7150/ijbs.69933. https://www.ijbs.com/v18p4560.htm
Other styles

File import instruction

Abstract

Graphic abstract

Gastric cancer (GC) is the most common gastrointestinal malignant tumor, and distant metastasis is a critical factor in the prognosis of patients with GC. Understanding the mechanism of GC metastasis will help improve patient prognosis. Studies have confirmed that urokinase-type plasminogen activator receptor (PLAUR) promotes GC metastasis; however, its relationship with anoikis resistance and associated mechanisms remains unclear. In this study, we demonstrated that PLAUR promotes the anoikis resistance and metastasis of GC cells and identified transcription Factor 7 Like 2 (TCF7L2) as an important transcriptional regulator of PLAUR. We also revealed that TCF7L2 is highly expressed in GC and promotes the anoikis resistance and metastasis of GC cells. Moreover, we found that TCF7L2 transcription activates PLAUR. Finally, we confirmed that TCF7L2 is an independent risk factor for poor prognosis of patients with GC. Our results show that TCF7L2 and PLAUR are candidate targets for developing therapeutic strategies for GC metastasis.

Keywords: gastric cancer, urokinase-type plasminogen activator receptor, transcription Factor 7 Like 2, transcription, anoikis


Citation styles

APA
Zhang, T., Wang, B., Su, F., Gu, B., Xiang, L., Gao, L., Zheng, P., Li, X.m., Chen, H. (2022). TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR. International Journal of Biological Sciences, 18(11), 4560-4577. https://doi.org/10.7150/ijbs.69933.

ACS
Zhang, T.; Wang, B.; Su, F.; Gu, B.; Xiang, L.; Gao, L.; Zheng, P.; Li, X.m.; Chen, H. TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR. Int. J. Biol. Sci. 2022, 18 (11), 4560-4577. DOI: 10.7150/ijbs.69933.

NLM
Zhang T, Wang B, Su F, Gu B, Xiang L, Gao L, Zheng P, Li Xm, Chen H. TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR. Int J Biol Sci 2022; 18(11):4560-4577. doi:10.7150/ijbs.69933. https://www.ijbs.com/v18p4560.htm

CSE
Zhang T, Wang B, Su F, Gu B, Xiang L, Gao L, Zheng P, Li Xm, Chen H. 2022. TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR. Int J Biol Sci. 18(11):4560-4577.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.